Nutromics

Nutromics is a private, pre-revenue medical technology company founded in 2018 and headquartered in Melbourne, Australia, with a significant presence in San Diego, USA. The company is developing a disruptive wearable diagnostic platform that uses microneedles and DNA-based biosensors to enable continuous, real-time monitoring of dynamic biomarkers, aiming to replace the inefficient single-point-in-time lab testing model. While the technology is in development and not yet FDA-approved, it targets a massive market opportunity across multiple chronic and acute conditions where trend data is critical for patient management. The company is led by a seasoned team of entrepreneurs and MedTech veterans and is advised by world-leading academic experts in DNA-based biosensing.

Wearable 'lab-on-a-patch' combining a microneedle array for interstitial fluid access with multiplexed Electrochemical Aptamer-Based (EAB) DNA sensors for continuous, real-time monitoring of multiple biomarkers.

Nutromics competes with large central lab incumbents (Quest, LabCorp), single-analyte continuous monitors (e.g., Dexcom, Abbott in glucose), and other emerging multi-analyte wearable sensor companies. Its key differentiator is the use of DNA-based EAB sensors for potential multiplexing and specificity across a wide range of non-glucose targets.